Drug Profile
PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals
Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-COHb; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; PP 007 -Prolong Pharmaceuticals; SanguinateLatest Information Update: 06 Apr 2023
Price :
$50
*
At a glance
- Originator Enzon Pharmaceuticals; Rutgers
- Developer Prolong Pharmaceuticals
- Class Anti-ischaemics; Antifibrotics; Haemoglobins; Polyethylene glycols; Recombinant proteins; Vascular disorder therapies
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Delayed graft function
- Phase II Cerebral ischaemia; Stroke; Vaso-occlusive crisis
- Preclinical Cystic fibrosis
- No development reported Beta-thalassaemia
Most Recent Events
- 09 Feb 2023 Pharmacodynamics data from preclinical studies in Stroke released by Prolong Pharmaceuticals
- 22 Nov 2022 Preclinical trials in Cystic fibrosis in USA (unspecified route) Before November 2022 (Prolong Pharmaceuticals pipeline, November 2022)
- 30 Sep 2022 Prolong Pharmaceuticals completes its phase I HEMERA-1 trials in Stroke in USA (IV) in October 2021 (NCT04677777)